• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assessment of CSF homovanillic acid levels distinguishes dementia with Lewy bodies from Alzheimer's disease.

作者信息

Kanemaru Kazutomi, Yamanouchi Hiroshi

出版信息

J Neurol. 2002 Aug;249(8):1125-6. doi: 10.1007/s00415-002-0753-x.

DOI:10.1007/s00415-002-0753-x
PMID:12420719
Abstract
摘要

相似文献

1
Assessment of CSF homovanillic acid levels distinguishes dementia with Lewy bodies from Alzheimer's disease.脑脊液高香草酸水平的评估可将路易体痴呆与阿尔茨海默病区分开来。
J Neurol. 2002 Aug;249(8):1125-6. doi: 10.1007/s00415-002-0753-x.
2
Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.高香草酸和5-羟色胺酸作为路易体痴呆合并阿尔茨海默病的生物标志物：一项尸检确诊研究。
PLoS One. 2017 Feb 6;12(2):e0171524. doi: 10.1371/journal.pone.0171524. eCollection 2017.
3
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.帕金森病患者脑脊液中α-突触核蛋白和tau 浓度：一项队列研究。
Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X.
4
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.脑脊液脂肪酸结合蛋白 3、α-突触核蛋白与阿尔茨海默病核心生物标志物在路易体疾病和阿尔茨海默病痴呆中的差异作用。
Alzheimers Res Ther. 2017 Jul 28;9(1):52. doi: 10.1186/s13195-017-0276-4.
5
Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.帕金森病痴呆、路易体痴呆和阿尔茨海默病患者的神经精神症状和 α-突触核蛋白特征。
J Neurol. 2018 Oct;265(10):2295-2301. doi: 10.1007/s00415-018-8992-7. Epub 2018 Aug 6.
6
Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.使用脑脊液标志物谱进行路易体痴呆、帕金森病和阿尔茨海默病的临床诊断。
J Alzheimers Dis. 2014;38(1):63-73. doi: 10.3233/JAD-130995.
7
Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.阿尔茨海默病脑脊液生物标志物可预测路易体痴呆的认知衰退。
Mov Disord. 2016 Aug;31(8):1203-8. doi: 10.1002/mds.26668. Epub 2016 Jun 14.
8
Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.血清心脏型脂肪酸结合蛋白和脑脊液tau蛋白：路易体痴呆的候选标志物。
Neurodegener Dis. 2007;4(5):366-75. doi: 10.1159/000105157. Epub 2007 Jul 6.
9
Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.脑脊液α-突触核蛋白在阿尔茨海默病与其他神经退行性疾病鉴别诊断中的应用。
Int Psychogeriatr. 2015 Sep;27(9):1429-38. doi: 10.1017/S1041610215000447. Epub 2015 Apr 8.
10
Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.脑脊液中的α-突触核蛋白可将突触核蛋白病（帕金森病、路易体痴呆、多系统萎缩）与阿尔茨海默病区分开来。
Alzheimer Dis Assoc Disord. 2012 Jul-Sep;26(3):213-6. doi: 10.1097/WAD.0b013e31823899cc.

引用本文的文献

1
CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease.CSF P-Tau181 及其他生物标志物在神经元核内包涵体病患者中的应用。
Neurology. 2023 Mar 7;100(10):e1009-e1019. doi: 10.1212/WNL.0000000000201647. Epub 2022 Dec 14.
2
Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.高香草酸和5-羟色胺酸作为路易体痴呆合并阿尔茨海默病的生物标志物：一项尸检确诊研究。
PLoS One. 2017 Feb 6;12(2):e0171524. doi: 10.1371/journal.pone.0171524. eCollection 2017.
3
Bridging molecular genetics and biomarkers in lewy body and related disorders.

本文引用的文献

1
18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies.18F-氟多巴PET研究纹状体多巴胺摄取在路易体痴呆诊断中的应用
Neurology. 2000 Nov 28;55(10):1575-7. doi: 10.1212/wnl.55.10.1575.
2
Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies.路易体痴呆患者脑脊液中β淀粉样蛋白42水平降低而tau蛋白水平正常。
Neurology. 2000 May 9;54(9):1875-6. doi: 10.1212/wnl.54.9.1875.
3
In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies.
连接路易体及相关疾病中的分子遗传学与生物标志物
Int J Alzheimers Dis. 2011;2011:842475. doi: 10.4061/2011/842475. Epub 2011 Jul 3.
4
Cognitive impairment and dementia in patients with Parkinson disease.帕金森病患者的认知障碍和痴呆。
Curr Top Med Chem. 2009;9(10):903-12.
Lancet. 1999 Aug 21;354(9179):646-7. doi: 10.1016/s0140-6736(99)01178-2.
4
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.路易体痴呆（DLB）临床与病理诊断的共识指南：DLB国际研讨会联盟报告
Neurology. 1996 Nov;47(5):1113-24. doi: 10.1212/wnl.47.5.1113.
5
Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases.阿尔茨海默病及其路易体变异型：尸检确诊病例的临床分析。
Am J Psychiatry. 1996 Oct;153(10):1269-73. doi: 10.1176/ajp.153.10.1269.
6
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.阿尔茨海默病的临床诊断：美国国立神经疾病与中风研究所-阿尔茨海默病及相关疾病协会工作组在卫生与公众服务部阿尔茨海默病特别工作组主持下的报告。
Neurology. 1984 Jul;34(7):939-44. doi: 10.1212/wnl.34.7.939.
7
Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease.阿尔茨海默病中脑脊液高香草酸（HVA）和5-羟吲哚乙酸（5-HIAA）水平降低的意义。
Neurobiol Aging. 1992 Jan-Feb;13(1):107-13. doi: 10.1016/0197-4580(92)90017-r.